OppFi (OPFI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now — Positive
OPFI Zacks Investment Research — October 30, 2025After losing some value lately, a hammer chart pattern has been formed for OppFi (OPFI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade — Positive
APGE Zacks Investment Research — October 30, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 69.3% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet — Positive
RLAY Zacks Investment Research — October 30, 2025The consensus price target hints at an 86.1% upside potential for Relay Therapeutics (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 27.2% Upside in James Hardie (JHX): Here's What You Should Know — Positive
JHX Zacks Investment Research — October 30, 2025The mean of analysts' price targets for James Hardie (JHX) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade — Positive
KMDA Zacks Investment Research — October 30, 2025The mean of analysts' price targets for Kamada (KMDA) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade — Positive
OCUL Zacks Investment Research — October 30, 2025The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LENZ Therapeutics, Inc. (LENZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now — Positive
LENZ Zacks Investment Research — October 30, 2025After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Anglo American's copper conundrum clouds the shine — Neutral
AAUKF CPER JJC NGLOY Proactive Investors — October 30, 2025Anglo American PLC's (LSE:AAL) third-quarter update was steady enough on the surface, yet Berenberg's latest note shows why investors might not want to relax just yet. The German bank has lifted its price target to 3,100p from 3,000p and kept its “Buy” rating, but the detail beneath the headline numbers tells a more nuanced story.
Enterprise Products Partners: Q3 Results Confirm Company Is Geared Towards Large-Scale Growth — Positive
EPD Seeking Alpha — October 30, 2025Enterprise Products Partners (EPD) is rated a "Buy" due to its robust infrastructure and strong growth prospects in energy transportation. EPD benefits from stable, fee-based revenues, geographic diversification, and expanding LNG and ethane export capacity, positioning it for strategic growth. Q3 2025 results show revenue beat and increased distributions, with a 27-year streak of payout growth and a forward yield of 6.98%, well above sector median.
Armstrong World Industries: Solid Growth Momentum And Upgraded Guidance (Rating Upgrade) — Positive
AWI Seeking Alpha — October 30, 2025Armstrong World Industries (AWI) upgraded to Buy as growth momentum and raised guidance justify its premium valuation. Q3 results showed 10% sales growth, strong EPS, and positive volume trends, with digital platforms Kanopi and ProjectWorks driving profitable expansion. AWI's office segment shows early signs of recovery, potentially removing a key overhang and unlocking additional growth and operating leverage.
Why Bread Financial Holdings (BFH) is a Top Momentum Stock for the Long-Term — Positive
BFH Zacks Investment Research — October 30, 2025The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Badger Meter (BMI) is a Strong Momentum Stock — Positive
BMI Zacks Investment Research — October 30, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Flowserve (FLS) is a Strong Momentum Stock — Positive
FLS Zacks Investment Research — October 30, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
InterDigital (IDCC) Tops Q3 Earnings and Revenue Estimates — Positive
IDCC Zacks Investment Research — October 30, 2025InterDigital (IDCC) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $1.79 per share. This compares to earnings of $1.63 per share a year ago.
Why Marathon Petroleum (MPC) is a Top Momentum Stock for the Long-Term — Positive
MPC Zacks Investment Research — October 30, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Paypal (PYPL) is a Strong Momentum Stock — Positive
PYPL Zacks Investment Research — October 30, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Select Medical (SEM) is a Top Momentum Stock for the Long-Term — Positive
SEM Zacks Investment Research — October 30, 2025Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Tenet Healthcare (THC) is a Top Momentum Stock for the Long-Term — Positive
THC Zacks Investment Research — October 30, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Universal Health Services (UHS) is a Strong Momentum Stock — Positive
UHS Zacks Investment Research — October 30, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Xylem (XYL) is a Strong Momentum Stock — Positive
XYL Zacks Investment Research — October 30, 2025Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
